Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Clinical Trials

PemBla: Pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC)

PEMBLA is a parallel group, open label, multi-centre, randomised, phase I/II marker-lesion study of intravesical or intravenous pembrolizumab in the treatment of non-muscle invasive bladder cancer.

This single-institution safety run-in phase will identify a tolerable dose of intravesical pembrolizumab using a within-patient dose escalation schedule. This tolerable dose will be taken forward into the phase II randomised portion of the study for the intravesical treatment arm. The phase II portion of the study will expand recruitment to more centres and look at the efficacy and safety of intravenous and intravesical delivery modalities of pembrolizumab to the bladder in 30 patients.

Joanna Moschandreas and Peter Dutton

Other clinical research

hyperthermic mitomycin treatment for bladder carcinoma: An Observational cohort study

This observational cohort study follows 97 people with high-risk non-muscle invasive urothelial carcinoma (bladder cancer). These people are given a well-established chemotherapy drug, mitomycin C. Unlike the standard protocol, the drug is administered with heat, which may improve how well the drug penetrates the cancer. 

The study will follow the patients and see how they respond to the new treatment protocol. It will look for any patient characteristics that can predict that response. The Nuffield Department of Surgical Sciences' SITU is running this study.

Susan Dutton and Virginia Chiocchia